- Home
- AVR vs DOUG Comparison
AVR vs DOUG Comparison
Compare AVR & DOUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVR
- DOUG
- Stock Information
- Founded
- AVR 1999
- DOUG 1911
- Country
- AVR Australia
- DOUG United States
- Employees
- AVR N/A
- DOUG N/A
- Industry
- AVR
- DOUG Building operators
- Sector
- AVR
- DOUG Real Estate
- Exchange
- AVR NYSE
- DOUG Nasdaq
- Market Cap
- AVR 162.1M
- DOUG 161.5M
- IPO Year
- AVR 2024
- DOUG N/A
- Fundamental
- Price
- AVR $3.33
- DOUG $2.82
- Analyst Decision
- AVR Strong Buy
- DOUG
- Analyst Count
- AVR 4
- DOUG 0
- Target Price
- AVR $16.50
- DOUG N/A
- AVG Volume (30 Days)
- AVR 202.3K
- DOUG 512.5K
- Earning Date
- AVR 08-16-2025
- DOUG 08-01-2025
- Dividend Yield
- AVR N/A
- DOUG N/A
- EPS Growth
- AVR N/A
- DOUG N/A
- EPS
- AVR N/A
- DOUG N/A
- Revenue
- AVR $2,493,000.00
- DOUG $1,048,791,000.00
- Revenue This Year
- AVR $33.26
- DOUG $17.61
- Revenue Next Year
- AVR $194.42
- DOUG N/A
- P/E Ratio
- AVR N/A
- DOUG N/A
- Revenue Growth
- AVR N/A
- DOUG 11.36
- 52 Week Low
- AVR $2.34
- DOUG $1.35
- 52 Week High
- AVR $8.79
- DOUG $3.20
- Technical
- Relative Strength Index (RSI)
- AVR N/A
- DOUG 57.28
- Support Level
- AVR N/A
- DOUG $2.69
- Resistance Level
- AVR N/A
- DOUG $3.03
- Average True Range (ATR)
- AVR 0.00
- DOUG 0.14
- MACD
- AVR 0.00
- DOUG 0.04
- Stochastic Oscillator
- AVR 0.00
- DOUG 66.67
About AVR ANTERIS TECHNOLOGIES GLOBAL CORP
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.